Advertisement

International Journal of Clinical Pharmacy

, Volume 34, Issue 5, pp 710–718 | Cite as

Difference of antihypertensive prescribing between office- and hospital-based clinics in Taiwan

  • Wei-Liang Chen
  • Tung-Wei Kao
  • Chung-Ching Wang
  • Yaw-Wen Chang
  • Li-Wei Wu
  • Mark L. Wahlqvist
  • Chih-Chieh ChouEmail author
Research Article
  • 233 Downloads

Abstract

Background The geographical location and medical facility may affect the pattern of antihypertensive prescriptions. Information regarding the correlation between the prescription and health care faculties in different geographical locations was lacking. Objective The aim of this study was to compare differences in the prescribing of antihypertensives between hospital-based clinics (hospital arm) and office-based clinics (office arm) in different geographical locations in Taiwan. Method We collected data from the National Health Insurance database of Taiwan to carry out a population-based, retrospective cohort analysis of 3,218,794 patients newly diagnosed with hypertension in the period January 1, 1997 to December 31, 2004. Eligible participants were classified into either of two groups based on the level of health care faculty: hospital arm and office arm. The covariates composed of age, gender, antihypertensive regimens, urbanization status, comorbidity, and Charlson comorbidity index. Results There were 2,028,784 cases (63.0 %) for the hospital arm and 1,190,010 (37 %) for the office arm. In the hospital-based arm, there were 168,933 (8.3 %) patients diagnosed with diabetes mellitus, 166,110 (8.2 %) patients diagnosed with coronary artery disease, 147,465 (7.3 %) patients diagnosed with cerebrovascular accident, 86,866 (4.3 %) patients diagnosed with chronic kidney disease, 74,525 (3.7 %) patients diagnosed with benign prostatic hyperplasia, 55,517 (2.7 %) patients diagnosed with congestive heart failure. The all comorbidities in the hospital arm had significantly higher proportions than those in the office arm (p < 0.001). The Charlson comorbidity index in the hospital arm was higher than that in the office arm (p < 0.001). Physicians who practiced in the office arm prescribed polytherapy less often than those in the hospital arm (OR = 0.68, 95 % CI: 0.67–0.68). For overall urbanization status, the adjusted OR of polytherapy prescriptions in the aging city (OR = 1.08, 95 % CI: 1.05–1.12) was higher than other type cities. The highest urbanization-specific OR of polytherapy prescriptions was observed for highly urbanized city in the hospital arm (OR = 1.20, 95 % CI: 1.18–1.23) and aging city in the office arm (OR = 1.42, 95 % CI: 1.21–1.67). In the both arm, patients with lower CCI showed decreased risk of polytherapy prescription. Conclusion The antihypertensive prescriptions in the clinical practices were different between the hospital arm and the office arm in the different health care, comorbidity, and urbanization status. During the study period, the proportion of antihypertensive polytherapy had declined.

Keywords

Charlson comorbidity index Hypertension Prescription patterns Polytherapy Taiwan Urbanization status 

Abbreviations

ATC

Anatomic therapeutic chemical

ACEIs

Angiotensin converting enzyme inhibitors

ARBs

Angiotensin II receptor blockers

ABs

α-blockers

BBs

β-blockers

BP

Blood pressure

CCBs

Calcium channel blockers

CI

Confidence interval

CCI

Charlson comorbidity index

HTN

Hypertension

ICD-9-CM

International classification of disease, ninth revision, clinical modification

JNC

The Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure

NHI

National Health Insurance

NAHST

Nutrition and Health Survey in Taiwan

OR

Odds ratio

SBP/DBP

Systolic blood pressure/diastolic blood pressure

TwSHHH

The Taiwanese Survey on hypertension, hyperglycemia, and hyperlipidemia

Notes

Acknowledgments

We would like to thank the National Council of Science and Tri-Service General Hospital. This study is based in part on data from the NHIRD provided by the Bureau of National Health Insurance, Department of Health, and managed by National Health Research Institutes. The interpretation and conclusions contained in this report do not represent those of Bureau of National Health Insurance, Department of Health, or National Health Research Institutes.

Funding

This study was supported by the National Council of Science and Tri-Service General Hospital.

Conflicts of interest

None.

References

  1. 1.
    Neal B, MacMahon S, Blood Pressure Lowering Treatment Trialists’ Collaboration. Effects of ACE inhibitors, calcium antagonists, and other blood-pressure-lowering drugs: results of prospectively designed overviews of randomized trials. Lancet. 2000;356:1955–64.PubMedCrossRefGoogle Scholar
  2. 2.
    Su TC, Bai CH, Chang HY, You SL, Chien KL, Chen MF, et al. Evidence for improved control of hypertension in Taiwan: 1993–2002. J Hypertens. 2008;26:600–6.PubMedCrossRefGoogle Scholar
  3. 3.
    Wu PH, Yang CY, Yao ZL, Lin WZ, Wu LW, Chang CC. Relationship of blood pressure control and hospitalization risk to medication adherence among patients with hypertension in Taiwan. Am J Hypertens. 2010;23:155–60.PubMedCrossRefGoogle Scholar
  4. 4.
    Bowman MA. Family physicians and internists: differences in practice styles and proposed reasons. J Am Board Fam Pract. 1990;3:43–9.PubMedGoogle Scholar
  5. 5.
    Al Khaja KA, Sequeira RP, Mathur VS, Damanhori AH, Abdul Wahab AW. Family physicians’ and general practitioners’ approaches to drug management of diabetic hypertension in primary care. J Eval Clin Pract. 2002;8:19–30.PubMedCrossRefGoogle Scholar
  6. 6.
    Chiang CW, Chiu HF, Chen CY, Wu HL, Yang CY. Trends in the use of lipid-lowering drugs by outpatients with diabetes in Taiwan, 1997–2003. Pharmacoepidemiol Drug Saf. 2008;17:62–9.PubMedCrossRefGoogle Scholar
  7. 7.
    Bureau of National Health Insurance. Introduction of Bureau of National Health Insurance. Accessed online 20 April 2006: http://www.nhi.gov.tw/webdata/webdata.asp?menu=1&menu_id=3&webdata_id=1159.
  8. 8.
    Department of Health, Executive Yuan. The status and health service statistics summary in Medical institutions in the Republic of China. Accessed online 20 April 2006: http://www.doh.gov.tw/statistic/data.
  9. 9.
    Charlson ME, Pompei P, Ales KL, MacKenzie CR. A new method of classifying prognostic comorbidity in longitudinal studies: development and validation. J Chronic Dis. 1987;40:373–83.PubMedCrossRefGoogle Scholar
  10. 10.
    Liu CY, Hung YT, Chuang YL, Chen YJ, Weng WS, Liu JS, et al. Incorporating development stratification of Taiwan townships into sampling design of large scale health interview survey. J Health Manag. 2006;4:1–22. (in Chinese).Google Scholar
  11. 11.
    Chen TJ, Chou LF, Hwang SJ. Patterns of ambulatory care utilization in Taiwan. BMC Health Serv Res. 2006;6:54.PubMedCrossRefGoogle Scholar
  12. 12.
    Chou CC, Hu KY, Wu NR, Cheng YH, Loh CH, Yeh MK. Changes in drug prescription utilization for diabetic and hypertensive outpatients after initiation of the National Health Insurance’s Global Budget Program in Taiwan. Med Sci Monit. 2008;14:PH33-9.Google Scholar
  13. 13.
    National Health Insurance Statistical Trend 2001. [cited 2006 Nov 9]. Available from: http://www.nhi.gov.tw/webdata/AttachFiles/Attach_2518_1_3-1-34.pdf.
  14. 14.
    Chiang TL. Analysis on trends for healthcare expenditures in Taiwan. Taiwan J Public Health. 2003;21:157–63.Google Scholar
  15. 15.
    Liu PH, Wang JD. Antihypertensive medication prescription patterns and time trends for newly-diagnosed uncomplicated hypertension patients in Taiwan. BMC Health Serv Res. 2008;8:133–44.PubMedCrossRefGoogle Scholar
  16. 16.
    Pan WH, Chang HY, Yeh WT, Hsiao SY, Hung YT. Prevalence, awareness, treatment and control of hypertension in Taiwan: results of Nutrition and Health Survey in Taiwan (NAHSIT) 1993–1996. J Hum Hypertens. 2001;15:793–8.PubMedCrossRefGoogle Scholar
  17. 17.
    Wen CP, Tsai SP, Chung WS. A 10-year experience with universal health insurance in Taiwan: measuring changes in health and health disparity. Ann Intern Med. 2008;148:258–67.PubMedGoogle Scholar
  18. 18.
    Report of the Joint National Committee on detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1988;148:1023–38.Google Scholar
  19. 19.
    Fifth Report of the Joint National Committee on detection evaluation, treatment of high blood pressure (JNC V). Arch Intern Med. 1993;153:154–83.Google Scholar
  20. 20.
    Sixth Report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Arch Intern Med. 1997;157:2413-46.Google Scholar
  21. 21.
    Chobanian AV, Bakris GL, Black HR, Cushman WC, Green LA, Izzo JL Jr, et al. Seventh report of the Joint National Committee on prevention, detection, evaluation, and treatment of high blood pressure. Hypertension. 2003;42:1206–52.PubMedCrossRefGoogle Scholar
  22. 22.
    Stafford RS, Monti V, Furberg CD, Ma J. Long-term and short-term changes in antihypertensive prescribing by office-based physicians in the United States. Hypertension. 2006;48:213–8.PubMedCrossRefGoogle Scholar
  23. 23.
    Chou CC, Lee MS, Ke CH, Chuang MH. Factors influencing the switch in the use of antihypertensive medications. Int J Clin Pract. 2005;59:85–91.PubMedCrossRefGoogle Scholar
  24. 24.
    Wang TJ, Ausiello JC, Stafford RS. Trends in antihypertensive drug advertising, 1985–1996. Circulation. 1999;99:2055–7.PubMedCrossRefGoogle Scholar
  25. 25.
    Fretheim A, Oxman AD. International variation in prescribing antihypertensive drugs: its extent and possible explanations. BMC Health Serv Res. 2005;5:21.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media B.V. 2012

Authors and Affiliations

  • Wei-Liang Chen
    • 1
  • Tung-Wei Kao
    • 1
  • Chung-Ching Wang
    • 1
  • Yaw-Wen Chang
    • 1
  • Li-Wei Wu
    • 1
  • Mark L. Wahlqvist
    • 2
  • Chih-Chieh Chou
    • 1
    Email author
  1. 1.Department of Family and Community MedicineTri-Service General Hospital, National Defense Medical CenterNeihuTaiwan
  2. 2.Center for Health Policy Research and DevelopmentNational Health Research InstitutesZhunanTaiwan

Personalised recommendations